Basic Information
| LncRNA/CircRNA Name | circ_0025202 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Tamoxifen | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR , western blot , luciferase reporter assay , RIP , actinomycin D and RNase R treatment , cell viability assay and cytotoxicity assay , colony formation assay , migration assay , cell apoptosis assay , Immunohistochemistry |
| Sample | BC tissues and adjacent breast tissues ,BC cell lines( MCF7 and T47D and the HEK293T cells) |
| Expression Pattern | down-regulated |
| Function Description | We found that hsa_circ_0025202 exhibited low expression in cancer tissues and was negatively correlated with lymphatic metastasis and histological grade. hsa_circ_0025202 could inhibit cell proliferation, colony formation, and migration and increase cell apoptosis and sensitivity to tamoxifen. hsa_circ_0025202 could act as a miRNA sponge for miR-182-5p and further regulate the expression and activity of FOXO3a. Functional studies revealed that tumor inhibition and tamoxifen sensitization effects of hsa_circ_0025202 were achieved via the miR-182-5p/FOXO3a axis. Moreover, in vivo experiments confirmed that hsa_circ_0025202 could suppress tumor growth and enhance tamoxifen efficacy. |
| Pubmed ID | 31153828 |
| Year | 2019 |
| Title | circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer |
External Links
| Links for circ_0025202 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |